More Positive news from DVAX!

Breakouts take time and patience, especially the big ones.  DVAX is going to be big when it happens, but you gotta be in it to win it!

Dynavax’s two phase 3 Heplisav trials cleared by DSMB to continue

BERKELEY, CA — (MARKET WIRE) — 05/27/10 — Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax’s two ongoing Phase 3 trials for HEPLISAV? has completed the second of its planned safety assessments. The evaluation included data from 2,264 subjects that received their first injection, 1,611 of whom received their first and second injections. The DSMB determined that the studies may continue without modification.

HEPLISAV is an innovative vaccine designed to protect against hepatitis B infection. The DSMB reviewed safety data from two ongoing multi-center Phase 3 trials evaluating HEPLISAV, one trial in adults 40 years and older, and a second trial in chronic kidney disease patients. The DSMB is comprised of an independent group of medical experts who are responsible for reviewing and evaluating subject safety data at regular intervals during the ongoing trials.

PRE MARKET : up 13.66% pre market @ $1.83